Nat Commun:孟德尔随机化分析评估维生素D与癌症易感性的关联性

2021-01-18 xiaozeng MedSci原创

维生素D是一种必需的脂溶性维生素,主要是由皮肤暴露于紫外线辐射所产生的。

维生素D是一种必需的脂溶性维生素,主要是由皮肤暴露于紫外线辐射所产生的。既往研究显示,除了维持肌肉骨骼健康外,维生素D还具有抗癌作用。

维生素D无论是在皮肤中产生或消耗,都需要经过两个羟基化步骤以成为活性形式。其中可通过测定第一步骤产生的25-羟基维生素D(25(OH)D)来确定维生素D的状态。


鉴于血清中25(OH)D的水平可以通过补充而轻易地改变,因此在预防癌症中评估维生素D的作用显得尤为重要。


在既往的关于25(OH)D和癌症的孟德尔随机(MR)研究中,通常采用少数的突变体进行研究并得出了二者没有相关性的结论。然而,这些研究并没有很好的解释水平基因多效性。

25(OH)D浓度增加与癌症风险之间的MR相关性模型

该研究采用了25(OH)D相关的较大的突变体集(74个SNP,之前的研究为为6个),研究人员通过统一的MR分析重新评估了25(OH)D与十种癌症之间的关系。


研究人员发现,除卵巢癌和基底细胞癌外,其余的癌症分析结果与先前的MR研究结果大致一致。然而,在多变量MR分析中调整了色素沉着相关变量后,基底细胞癌的变化减弱。


综上,该研究结果显示,较低水平的25(OH)D不太可能是大多数癌症的因果风险因素,该研究结果也提供相比于之前研究更精确的置信区间。


原始出处:

Ong, JS., Dixon-Suen, S.C., Han, X. et al. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nat Commun 12, 246 (11 January 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087879, encodeId=91c1208e87931, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Mar 01 10:09:58 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884908, encodeId=31a71884908ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 18:09:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460580, encodeId=490114605803c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Wed Jan 20 14:09:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038989, encodeId=47d3103898988, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue Jan 19 02:09:58 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-03-01 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087879, encodeId=91c1208e87931, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Mar 01 10:09:58 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884908, encodeId=31a71884908ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 18:09:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460580, encodeId=490114605803c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Wed Jan 20 14:09:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038989, encodeId=47d3103898988, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue Jan 19 02:09:58 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-03-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087879, encodeId=91c1208e87931, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Mar 01 10:09:58 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884908, encodeId=31a71884908ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 18:09:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460580, encodeId=490114605803c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Wed Jan 20 14:09:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038989, encodeId=47d3103898988, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue Jan 19 02:09:58 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087879, encodeId=91c1208e87931, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Mar 01 10:09:58 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884908, encodeId=31a71884908ff, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 18:09:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460580, encodeId=490114605803c, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Wed Jan 20 14:09:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038989, encodeId=47d3103898988, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue Jan 19 02:09:58 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-01-19 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

相关资讯

World Allergy Organ J:产前维生素D补充和儿童呼吸道健康:随机对照试验系统回顾和元分析

对母体维生素D状态和呼吸道过敏性疾病风险的观察性研究的系统回顾和元分析表明,母亲在怀孕期间补充维生素D可以降低后代复发性喘息或哮喘的风险。最近,有研究人员进行了随机对照试验的元分析,调查产前补充维生素

Nat Commun:老年人补充维生素D会如何影响肠道微生物组?

其对567名老年男性进行横断面分析,利用LC-MSMS量化血清维生素D代谢物,并从16S核糖体RNA基因测序数据中定义粪便亚操作分类单元。

Dig Dis Sci:维生素D缺乏导致结肠局部肾素-血管紧张素系统的激活而加剧结肠炎症

炎性肠病(IBD)是人类胃肠道的慢性疾病,由克罗恩病(CD)和溃疡性结肠炎(UC)组成。

Clin Nutrition:维生素D缺乏与脑组织健康程度存在关联

有文献已经证实,维生素D缺乏与痴呆症的风险增加有关。

Clin Exp Allergy:血清25-羟基维生素D水平与过敏性鼻炎、过敏性致敏和非过敏性鼻炎之间无关联

之前的观察性研究没有发现血清25-羟维生素D(25(OH)D)水平与过敏性鼻炎(AR)或过敏性致敏(AS)之间有结论性的关联。最近,有研究人员采用双样本孟德尔随机化(MR)方法,调查了25(OH)D水

Clin Nutrition: 25(OH)D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

我们已经知道,维生素D功能不足与多种癌症类型的临床结局较差有关。然而,其在弥漫性大B细胞淋巴瘤(DLBCL)患者中的作用仍不清楚。